Navigation Links
Sangamo BioSciences Reports Fourth Quarter And Full Year 2012 Financial Results
Date:2/6/2013

RICHMOND, Calif., Feb. 6, 2013 /PRNewswire/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) today reported fourth quarter and full year 2012 financial results and accomplishments.

(Logo: http://photos.prnewswire.com/prnh/20130102/SF35903LOGO)

For the fourth quarter ended December 31, 2012, Sangamo reported a consolidated net loss of $3.5 million, or $0.07 per share, compared to a net loss of $6.4  million, or $0.12 per share, for the same period in 2011. As of December 31, 2012, the Company had cash, cash equivalents, marketable securities and interest receivable of $76.3 million.

Revenues were $8.9 million for the fourth quarter of 2012, compared to $4.7 million for the same period in 2011.  Fourth quarter 2012 revenues were generated from the Company's collaboration agreements with Shire AG (Shire), Dow AgroSciences (DAS) and Sigma-Aldrich Corporation (Sigma), and research grants. The revenues recognized for the fourth quarter of 2012 consisted of $8.5 million in collaboration agreements and $0.4 million in research grants, compared to $3.2 million and $1.5 million, respectively, for the same period in 2011.

The increase in collaboration agreement revenues was primarily due to the Company's collaboration and license agreement with Shire established in January 2012.  Pursuant to the agreement, Sangamo received an upfront payment of $13.0 million, which is being amortized on a straight-line basis over the initial six-year research term, of which the Company recognized $0.5 million as revenue for the fourth quarter of 2012. Sangamo also recognized $4.3 million of revenues related to research services performed under the collaboration agreement with Shire in the fourth quarter. The increase in collaboration agreement revenues for the fourth quarte
'/>"/>

SOURCE Sangamo BioSciences, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Sangamo BioSciences to Webcast Analyst Briefing on Thursday, December 6, 2012
2. Sangamo BioSciences Reports Second Quarter 2012 Financial Results
3. Neurocrine Biosciences To Present At The Leerink Swann Global Healthcare Conference 2013
4. Neurocrine Biosciences Announces Conference Call And Webcast To Present Fourth Quarter And Year-End 2012 Financial Results
5. Neurocrine Biosciences Announces Additional European And United States Patents Issued On Proprietary VMAT2 Inhibitor
6. IntelliCell BioSciences Receives Notice of Allowance for its US Patent for "Ultrasonic Cavitation of Adipose Tissue to Produce Stromal Vascular Fraction Regenerative Cells"
7. Regado Biosciences, Inc. to Present at the Oppenheimer 23rd Annual Healthcare Conference in New York, NY
8. Pressure BioSciences Announces Conversion of All Remaining Series E Convertible Preferred Stock by Ironridge BioPharma
9. Neurocrine Biosciences To Present At Deutsche Banks 2012 dbAccess BioFEST
10. Pressure BioSciences Partners with Constant Systems to Significantly Expand Product Offerings and International Distribution
11. Pressure BioSciences, Inc. to Discuss Third Quarter 2012 Financial Results and Provide Business Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... IRVING, Texas , Jan. 15, 2014  Novation, the ... company, awarded several new IT value-added reseller (VAR) national ... with IT goods and services at lower costs. These ... value-added services such as initiative assistance and ongoing IT ...
(Date:1/15/2014)... 15, 2014 Massachusetts General Hospital (MGH), the ... ) announced today that they have launched a ... therapeutic targets and develop novel therapies for inflammatory ... millions worldwide. The MGH-Broad-Amgen collaboration brings together scientists ...
(Date:1/15/2014)... Jan. 15, 2014  Humberto C. Antunes,  Galderma  worldwide CEO, ... the Journal of Drugs in Dermatology (JDD) ... (ODAC). The event is January 17-20, 2014, at the Omni Orlando ... The ODAC is a distinguished event ...
Breaking Medicine Technology:New Novation Information Technology VAR Contracts Offer Significant Savings to Hospitals 2Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 2Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 4Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4
... CHADDS FORD, Pa. , Jan. 19 ... partners, Teikoku Seiyaku Co., Ltd. and Teikoku Pharma USA, Inc. ... Inc. advising of the filing of an Abbreviated New Drug ... (lidocaine topical patch 5%). , The company is currently reviewing ...
... Partners Forge Collaboration to Fund Discovery of New Drugs that Target the ... MILAN, Italy , Jan. 19 Fast Forward, LLC ... Sclerosis Society, and the Juvenile Diabetes Research Foundation (JDRF) , ... diabetes in the world today announced a collaborative partnership with Axxam SpA ...
Cached Medicine Technology:Endo Pharmaceuticals Announces Receipt of Paragraph IV Certification 2Endo Pharmaceuticals Announces Receipt of Paragraph IV Certification 3Endo Pharmaceuticals Announces Receipt of Paragraph IV Certification 4Endo Pharmaceuticals Announces Receipt of Paragraph IV Certification 5Fast Forward, Juvenile Diabetes Research Foundation and Axxam SpA Join Forces to Accelerate Development of Treatments for Multiple Sclerosis and Type 1 Diabetes 2Fast Forward, Juvenile Diabetes Research Foundation and Axxam SpA Join Forces to Accelerate Development of Treatments for Multiple Sclerosis and Type 1 Diabetes 3Fast Forward, Juvenile Diabetes Research Foundation and Axxam SpA Join Forces to Accelerate Development of Treatments for Multiple Sclerosis and Type 1 Diabetes 4Fast Forward, Juvenile Diabetes Research Foundation and Axxam SpA Join Forces to Accelerate Development of Treatments for Multiple Sclerosis and Type 1 Diabetes 5
(Date:4/23/2014)... benefits of probiotics, antioxidants and other nutritional compounds, more ... industry is getting in on the action. But legitimate ... the industry is responding with clinical research to shore ... Chemical & Engineering News (C&EN), the weekly ... M. Bomgardner, a senior editor at C&EN, writes that ...
(Date:4/23/2014)... Five for-profit and non-profit organizations in Washington ... Proof of Concept grants to accelerate maturation of ... the Life Sciences Discovery Fund (LSDF) announced today. ... grant to the Washington Biotechnology & Biomedical Association ... train the next generation of entrepreneurs and help ...
(Date:4/23/2014)... of Midlife Occupational and Leisure Time Physical Activity on ... activity in midlife increases the risk of mobility limitation ... risk. This is found in a study which followed ... study was conducted at the Gerontology Research Center in ... Heavy physical labor is often repetitive, wears the body ...
(Date:4/23/2014)... that proliferation of endogenous neural precursor cells cannot ... axons. From the perspective of neural plasticity, Dr. ... in China observed the effects of functional electrical ... and expression of basic fibroblast growth factor and ... the infarct side. The researchers found that functional ...
(Date:4/22/2014)... industry leaders visited the New Jersey Institute of ... S. Bloom for the launch of the New ... provides a new model for business innovation through ... assets and investment. U.S. Senator Cory Booker, Panasonic ... Taylor, New Jersey Lieutenant Governor Kim Guadagno, New ...
Breaking Medicine News(10 mins):Health News:LSDF announces commercialization grants and Entrepreneur Mentoring Program 2Health News:Midlife occupational and leisure-time physical activity limits mobility in old age 2Health News:Government and industry leaders herald launch of NJIT's New Jersey Innovation Institute 2
... cultural changes that promote patient safety.ENGLEWOOD, Colo., March ... technology for the safe handling, packaging and administration ... targeted campaign recognizing patient safety. The year-long ... the need for a true cultural change in ...
... Air Methods Corporation (Nasdaq: AIRM ), the ... and net income for the year and fourth quarter ended ... $498.8 million compared to $396.3 million in the prior year. ... per diluted share, in the prior year to $19.3 million, ...
... release is available in French . ... manufacturing sector specifically those working in metallurgy and ... governmental norms. , According to a new study from ... Institut national de sant publique du Qubec, extra workplace ...
... the first time that maintenance therapy with the ... (CVP) therapy improves progression-free survival in patients with stage ... of NYU Langone Medical Center, lead author of a ... Journal of Clinical Oncology . , In a ...
... No serious side effects are found in latest ... News) -- A third-generation tissue-cultured smallpox vaccine shows ... smallpox bioterrorism has prompted reconsideration of the need ... associated with first-generation vaccines #133; have raised obstacles ...
... BenefitsWATSONVILLE, Calif., March 10 For millions of Americans ... that improve health and longevity, the latest research results ... published in the scientific journal, Metabolism, found ... cholesterol.The study, conducted by David J.A. Jenkins, MD, PhD, ...
Cached Medicine News:Health News:Baxa Corporation Launches 'Culture of Safety' Campaign to Recognize National Patient Safety Awareness Week 2Health News:Baxa Corporation Launches 'Culture of Safety' Campaign to Recognize National Patient Safety Awareness Week 3Health News:Air Methods Announces Year 2008 Financial Results and Provides First Quarter 2009 Update 2Health News:Air Methods Announces Year 2008 Financial Results and Provides First Quarter 2009 Update 3Health News:Air Methods Announces Year 2008 Financial Results and Provides First Quarter 2009 Update 4Health News:Air Methods Announces Year 2008 Financial Results and Provides First Quarter 2009 Update 5Health News:Air Methods Announces Year 2008 Financial Results and Provides First Quarter 2009 Update 6Health News:Noisy workplaces can make workers deaf 2Health News:Study shows that maintenance rituximab is useful for advanced indolent lymphoma 2Health News:Japanese Researchers Develop New Smallpox Vaccine 2Health News:Spoonfuls of Strawberries Help the Cholesterol Go Down 2Health News:Spoonfuls of Strawberries Help the Cholesterol Go Down 3
... operation in the cath lab has ... daily clinical routine as cardiologists balance ... and lower costs. With AXIOM Sensis, ... system that helps to master both ...
... Artis dTC is a versatile solution designed ... department from preparation to diagnosis and ... With AXIOM Artis dTC, your cath lab ... department that leaves you free to concentrate ...
... BC is a biplane cardiovascular ... ideal for cardiological diagnostics and ... architecture enables you to optimally ... focus on:, Interventional cardiology, ...
MAGNETOM Symphony, an imaging system that offers 1.5T performance and top image quality in a short bore design....
Medicine Products: